OPA1 , a molecular regulator of dilated cardiomyopathy
Journal of Cellular and Molecular Medicine · 2023-10 · 27 (20) · 3017-3025
DOI: 10.1111/jcmm.17918 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 21.08.2023. Verfasst von Jiaqi Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Apoptosis, Cardiomyopathy, Dilated, GTP Phosphohydrolases, Mitochondrial Dynamics. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dilated cardiomyopathy (DCM) is a disease with no specific treatment, poor prognosis and high mortality. During DCM development, there is apoptosis, mitochondrial dynamics imbalance and changes in cristae structure. Optic atrophy 1 (OPA1) appears at high frequency in these three aspects. DCM LMNA (LaminA/C) gene mutation can activate TP53, and the study of P53 shows that P53 affects OPA1 through Bak/Bax and OMA1 (a metalloprotease). OPA1 can be considered the missing link between DCMp53 and DCM apoptosis, mitochondrial dynamics imbalance and changes in cristae structure. OPA1 regulates apoptosis by regulating the release of cytochrome c from the mitochondrial matrix through CJs (crisp linkages, located in the inner mitochondrial membrane) and unbalances mitochondrial fusion and fission by affecting mitochondrial inner membrane (IM) fusion. OPA1 is also associated with the formation and maintenance of mitochondrial cristae. OPA1 is not the root cause of DCM, but it is an essential mediator in P53 mediating the occurrence and development of DCM, so OPA1 also becomes a molecular regulator of DCM. This review discusses the implication of OPA1 for DCM from three aspects: apoptosis, mitochondrial dynamics and ridge structure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
- Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College/National Center for Cardiovascular Diseases, Beijing, China.
ORCID-Profile: Jiaqi Chen
Zitieren
APA
Chen, J., Shao, J., Wang, Y., Wu, K., & Huang, M. (2023). OPA1 , a molecular regulator of dilated cardiomyopathy. Journal of Cellular and Molecular Medicine, 27(20), 3017-3025. https://doi.org/10.1111/jcmm.17918
Vancouver
Chen J, Shao J, Wang Y, Wu K, Huang M. OPA1 , a molecular regulator of dilated cardiomyopathy. Journal of Cellular and Molecular Medicine. 2023;27(20):3017-3025. doi:10.1111/jcmm.17918
BibTeX
@article{Chen2023,
author = {Chen, Jiaqi and Shao, Jianan and Wang, Yaoyao and Wu, Kangxiang and Huang, Mingyuan},
title = {OPA1 , a molecular regulator of dilated cardiomyopathy},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
volume = {27},
number = {20},
pages = {3017--3025},
doi = {10.1111/jcmm.17918}
}
EUVIMED